Display options
Cite
Gebremeskel TG, Gebreyowhans D, Abrha Gesesew H, et al. Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study. HIV AIDS (Auckl). 2021;13:641-649doi: 10.2147/HIV.S310419.
Gebremeskel, T. G., Gebreyowhans, D., Abrha Gesesew, H., & Ward, P. R. (2021). Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study. HIV/AIDS (Auckland, N.Z.), 13641-649. https://doi.org/10.2147/HIV.S310419
Gebremeskel, Teferi Gebru, et al. "Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study." HIV/AIDS (Auckland, N.Z.) vol. 13 (2021): 641-649. doi: https://doi.org/10.2147/HIV.S310419
Gebremeskel TG, Gebreyowhans D, Abrha Gesesew H, Ward PR. Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study. HIV AIDS (Auckl). 2021 Jun 09;13:641-649. doi: 10.2147/HIV.S310419. eCollection 2021. PMID: 34135642; PMCID: PMC8200146.
Copy Download .nbib Format: NLM
Share it on

HIV AIDS (Auckl). 2021 Jun 09;13:641-649. doi: 10.2147/HIV.S310419. eCollection 2021.

Incidence and Predictors of Severe Adverse Drug Reaction Among Patients on Antiretroviral Therapy in Tigray, Ethiopia: A Retrospective Cohort Study.

HIV/AIDS (Auckland, N.Z.)

Teferi Gebru Gebremeskel, Destalem Gebreyowhans, Hailay Abrha Gesesew, Paul R Ward

Affiliations

  1. Department of Reproductive Health, College of Health Sciences, Aksum University, Aksum, Ethiopia.
  2. School of Medicine, College of Medicine and Health Science, Aksum University, Aksum, Ethiopia.
  3. Discipline of Public Health, Flinders University, Adelaide, South Australia, Australia.
  4. Department of Epidemiology, College of Health Sciences, Mekele University, Mekele, Ethiopia.

PMID: 34135642 PMCID: PMC8200146 DOI: 10.2147/HIV.S310419

Abstract

BACKGROUND: The aim of the present study was to assess the incidence and predictors of severe adverse drug reactions among patients on antiretroviral therapy (ART) in Tigray, North Ethiopia.

METHODS: We employed four years retrospective cohort study using a structured data extraction sheet. The study populations were HIV patients on ART follow-up from January 2017 to February 2020 in the study area. Severe adverse drug reaction (ADR) was an outcome variable and defined as having any one of the complaints related to ARV drug reaction due to regimen change, discontinuation, and/or in-patient care. Data were collected using a structured data extraction sheet. A Cox proportional hazard regression model was used to determine the relationship between the predictors and the outcome variable. The mean survival time of the cohort was estimated using the Kaplan-Meier method.

RESULTS: The incidence rate of ADRs was 3.6 (95%CI: 2.9-4.35) per 100-person years. HIV patients with no formal education (adjusted hazard ratio=1.58, 95%CI: 1.03-2.41), with experience of regimen change (adjusted hazard ratio=1.59, 95%CI: 1.12-2.91), who ever took other medication (adjusted hazard ratio=1.49, 95%CI: 1.05-2.15) and with lower body mass index (adjusted hazard ratio=3.24, 95%CI: 1.18-4.91) were more likely to develop severe adverse drug reaction.

CONCLUSION: ADRs were diagnosed an inconsiderable number of HIV patients on ART and factors were patient and drug-related. To minimize it, special attention is sought for patients with no formal education, previous regime change, whoever took other medication, and who have lower body mass index levels.

© 2021 Gebremeskel et al.

Keywords: adverse drug reactions; antiretroviral therapy; human immunodeficiency virus

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Am Rev Respir Dis. 1987 Sep;136(3):570-4 - PubMed
  2. J Young Pharm. 2012 Oct;4(4):250-60 - PubMed
  3. Clin Med (Lond). 2016 Oct;16(5):481-485 - PubMed
  4. BMC Infect Dis. 2017 Jun 27;17(1):453 - PubMed
  5. PLoS One. 2014 Mar 10;9(3):e91028 - PubMed
  6. BMC Clin Pharmacol. 2012 Feb 27;12:7 - PubMed
  7. AIDS. 2002 Jan 4;16(1):75-83 - PubMed
  8. J Am Acad Orthop Surg. 2021 Feb 1;29(3):e132-e142 - PubMed
  9. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1166-9 - PubMed
  10. Saudi Pharm J. 2014 Apr;22(2):83-94 - PubMed
  11. PLoS One. 2018 Oct 11;13(10):e0205426 - PubMed
  12. Ethiop J Health Sci. 2017 Feb;27(Suppl 1):39-52 - PubMed
  13. PLoS One. 2017 Dec 21;12(12):e0189322 - PubMed
  14. AIDS Res Ther. 2016 Feb 17;13:10 - PubMed
  15. Drug Saf. 2015 Jul;38(7):629-39 - PubMed
  16. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7 - PubMed
  17. Pan Afr Med J. 2014 May 07;18:25 - PubMed
  18. PLoS One. 2014 Apr 02;9(4):e93106 - PubMed

Publication Types